Anthropic acquires Mithril Medicine to accelerate clinical trials

Anthropic has acquired Mithril Medicine, a one-person company founded by Cody Tranbarger, a Harvard MBA and former Goldman Sachs analyst. Tranbarger used Anthropic’s Claude model to manage contracts, logistics, and experiments with 11 external labs, taking a muscular dystrophy treatment from concept to proof of principle in mice in less than 18 months. The acquisition coincides with a new partnership with Bristol-Myers Squibb to enhance early-stage clinical trial planning. Anthropic aims to have a drug ready for clinical trials by the end of 2028, a timeline significantly faster than the typical four-to-seven-year industry standard. Analysts noted the move signals a strategic shift for Anthropic to own drug discovery outcomes, such as patents, rather than merely selling access to AI models, potentially ahead of an IPO. While some critics, including Scorpion Capital, questioned Tranbarger’s scientific background, others viewed the acquisition as a validation of the one-person AI company thesis. The deal underscores a broader trend among AI labs to integrate directly into high-value verticals to capture the full value of their intelligence.